FTC challenges Illumina’s purchase of cancer test manufacturer

Illumina’s proposed $8 billion acquisition of Grail could give it sole control over the market for certain cancer-screening tests, the Federal Trade Commission has alleged in a lawsuit seeking to block the merger.


Get unlimited access to all Global Competition Review content